According to a new report, published by KBV research, The Global Veterinary Pain Management Market size is expected to reach $2.5 billion by 2030, rising at a market growth of 6.2% CAGR during the forecast period.
The Livestock Animal segment is leading the Global Veterinary Pain Management Market by Animal type in 2022; thereby, achieving a market value of $1.6 billion by 2030. This is due to an increase in the number of chronic diseases, increased awareness among animal healthcare groups, and high expenditures on veterinary treatment in developing nations. Lameness, an accelerated rate of breathing, an increase in vocalization, an expiratory grunt, and teeth grinding are some apparent symptoms of discomfort in livestock. The most often prescribed medications are NSAIDs, a2 adrenergic drugs, and local anesthetics.
The Others segment is showcasing a CAGR of 6.8% during (2023 - 2030). The primary driver of the regional market expansion is the rise in the number of veterinary drugstores in urban areas. Furthermore, it is anticipated that the market will expand during the projection period as a result of the easy availability of NSAIDs, anesthetics, and opioids for veterinary pain management.
The Osteoarthritis segment acquired maximum revenue share in the Global Veterinary Pain Management Market by Indication in 2022; thereby, achieving a market value of $1.5 billion by 2030. In companion animals like dogs and cats, arthritis is a common disease that develops when the cartilage within a joint is damaged. As companion animals become increasingly fatty and overweight, the prevalence of arthritis is expected to rise, creating new opportunities for the market in this segment as these animals often suffer from acute or chronic pain.
The Opioids segment is experiencing a CAGR of 7.2% during (2023 - 2030). This is due to their enduring effectiveness in the treatment of pain. For moderate to severe surgical pain in several animal species, opioids are acknowledged to be the most effective analgesics currently on the market.
The North America region dominated the Global Veterinary Pain Management Market by Region in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $872.3 million by 2030. The Europe region is poised to grow at a CAGR of 6% during (2023 - 2030). Additionally, The Asia Pacific region would exhibit a CAGR of 6.9% during (2023 - 2030).
Full Report: https://www.kbvresearch.com/veterinary-pain-management-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Boehringer Ingelheim International GmbH, Bayer AG, Zoetis, Inc., Merck & Co., Inc., Elanco Animal Health, Inc., Zomedica Corp. (Assisi Animal Health), Norbrook Laboratories Limited, Ceva Santé Animale, Dechra Pharmaceuticals PLC, and Vetoquinol SA (Soparfin SCA)
By Animal type
By End-Use
By Indication
By Product
By Geography
Companies Profiled
Unique Offerings 
